Microsoft powerpoint - diabetes medications april 2011.ppt

“Making Clinical Sense of Diabetes
Types of Diabetes
Type 1 DM = Beta Cell Destruction, absolute insulin deficiency Type 2 DM = Ranges from predominantly insulin resistance with relative insulin deficiency to predominantly insulin deficiency with insulin Gestational DM (GDM) = glucose intolerance with Pre-Diabetes = Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) Pathophysiology
Beta Cell Function & Glucagon
Insulin Deficiency + Insulin Resistance = Progressive Beta cell decline = inadequate insulin Hyperglycemia Type 2 DM, Gestational DM, Pre- Absolute Deficiency of Insulin = Hyperglycemia Glucagon is not suppressed during the post prandial Hepatic glucose production is increased during the fasting period Relative contributions of postprandial (□) and fasting (▪) hyperglycemia (%) to the overall diurnal hyperglycemia over quintiles of HbA1c Optimal Diabetes Medication
Glycemic Targets
Address patient concerns, i.e. hypo, weight gain, side Oral Medications
Question #1
• Drugs in the sulfoynlurea class are the drug of Pancreas – stimulate insulin production choice for newly diagnosed Type 2 diabetes Liver – decrease hepatic glucose production Intestines/gut – decrease absorption of CHO; gut Sulfonylureas
Efficacy: Reduce A1C 1-2%, decrease FPG 60 Work best in first 5-10 years of diabetes Meglinitides
Meglinitides (continued)
Take 0-15 min before meals and large snacks Efficacy: Reduce A1C 1-2%, Decrease FGB, PPG Question #2
Question #3
Which of the following is an important counseling Metformin is one of the best choices to target post c. May cause GI upsetd. If you skip a meal, skip Prandin Biguanides
Biguanides (continued)
Action: Decrease hepatic gluconeogenesis and Efficacy: Reduce A1C 1-2%, decrease FPG 60-70 mg/dl, weight loss, may decrease cholesterol Contraindicated if serum Cr > 1.4 mg/dl women, Thiazolidenediones (TZDs)
TZDs (continued)
Alpha-Glucosidase Inhibitors
AGIs (continued)
Action: Delay digestion and absorption of CHO Inhibit intestinal enzyme →slow breakdown of complex Decrease FBG (20-30 mg/dl) and PPG (40-50 mg/dl) DPP-4 Inhibitors
DPP-4 Inhibitors (continued)
Ingestion of food→release of incretin hormones GLP-1 and GIP→Beta & Alpha cell stimulation In DM, DPP-4 enzyme breaks down GLP-1 & GIP, so that the beta/alpha cells have decreased These inhibit the DDP-4 enzyme→prolongs life of GLP-1 Combination Meds
Incretin Mimetics
Action: increase insulin secretion, B-cell growth/replication, slows gastric emptying, may • Actosplus Met (pioglitazone/metformin) decrease food intake, suppresses glucagon secretion • Duetact (pioglitazone/glimepiride) • Janumet (sitagliptin/metformin) • Avandaryl (rosiglitazone/glimepiride) • Kombiglyze XR (metformin/saxagliptin) Incretin Mimetics (continued)
Question #4
Which medication(s) do not have the side effect of Risks: nausea, not with CrCL< 30mg/dl, not with Amylinomimetc
Amylinomimetic (continued)
Action: Hormone amylin co-secreted by beta cells in Dose T1DM 15 mcg→60mcg 4 step titration Dose T2 DM 60mcg→120 mcg 2 step titration Deficiencies relative to beta cell function Reduces food intake, appetite suppression Dopamine Agonist
Bile Acid Sequestrant
Used with diet & exercise in Type 2 DM GI side effects (constipation, dyspepsia, nausea) Insulin Therapy
Insulin: Basal/Bolus Regimen
NPH, detemir (Levemir), glargine (Lantus) Detemir & glargine more physiologic for basal Basal/Bolus Regimen
Bolus insulin targets meals/snacks and post prandial glucose • Add rapid insulin to next largest meal Insulin
Case Study #1
S.B. is a 42 yo AAF, 5 year hx Type 2 DM. PMH includes HTN, Ht 61 inches, wt 163 #; labs A1C 10.2%, HDL 55 mg/dl, LDL 83 mg/dl, TG 111, TC 167, SCr 0.9. Meds: lisinopril, metformin 1000 mg bid, glyburide 5 mg bid, asa 81 mg qd.
Q: Which of the following is the most effective approach to improve SBs glycemic control? Case Study #1
Case Study #2
T.L. is a 72 yo Caucasian male with 15 year hx DMT2. Meds: glipizide 10 mg bid, precose 25 mg tid ac, simvastatin. FBG 113-190, tests BG only in the am. BP 143/63, 6 ft 1 in, 220 #, SCr 1.7, HDL 26, LDL 79, TG 182, TC 120. A1C 8.2%. He reports he often forgets to take the precose.
Q: Which of the following is the most effective approach to improve TLs glycemic control? Case Study #2
Case Study #3
J.R. is a 40 yo AAM, 20 yr hx DMT2. Patient currently taking Lantus 20 units HS, glimepiride 4 mg qam, metformin 1000 mg bid, atenolol, lisinopril, pravachol, asa 81 mg. SMBG FBG 180s, before dinner or HS up to 200s-300s.
c. Decrease precose, add januvia 50 mg qd Ht: 5’8”, wt 177#. Review of diet indicates patient is not overeating. A1C 11.2, LDL 98, HDL 41, TG 144, TC 177. Q: Which of the following is the most effective approach to improve JRs glycemic control? Case Study #3
c. Increase Lantus 1 unit daily until FBG less than


Mg42849g tlc member guide_v2_mg42849g tlc member guide_v2

MG42849G TLC MEMBER GUIDE_v2_MG42849G TLC MEMBER GUIDE_v2 6/15REMEMBER TO SHARE THIS GUIDE WITH YOUR DOCTOR. MG42849G TLC MEMBER GUIDE_v2_MG42849G TLC MEMBER GUIDE_v2 6/15 Introduction Welcome to your three-tier outpatient prescription drug plan! Your three-tier drug program gives you access to all medications in coveredclasses within the confines of your plan’s benefit design. This pl

Implementation of Electronic Dividend Payment (“eDividend”) We are pleased to inform you of the provision of eDividend to shareholders, by Jerasia Capital Berhad (“ the Company ”). The eDividend refers to the payment of cash dividends by the Company directly into the shareholders’ bank accounts. One of the main objectives of implementing eDividend is to promote greater effici

Copyright © 2010-2019 Pdf Physician Treatment